文献速递产科

从医疗卡到摇篮:阿肯色州孕妇医用大麻购买情况分析

From card to cradle: examining medical cannabis purchasing among pregnant women in Arkansas.
PubMed 文献 · Am J Obstet Gynecol MFM · 2025-11-27

本研究对2019年5月11日至2022年8月31日阿肯色州72,992例妊娠进行描述性探索性分析,其中1,185例(1.62%)在孕期购买医用大麻。孕妇日均购买THC为137.36(170.04)mg/d,超过FDA批准的非孕成人治疗剂量范围,持续使用者在孕期日均THC购买量是起始使用者的1.82倍。

要点

  • 阿肯色州72,992例妊娠中1,185例(1.62%)孕期购买医用大麻,其中65.3%为孕前已用并持续者。
  • 孕期日均购买THC为137.36(170.04)mg/d,超过FDA批准的非孕成人治疗剂量范围。
  • 持续使用者孕期日均THC购买量是起始使用者的1.82倍(P<.0001)。

核心结论

  • 孕期日均购买THC超过FDA批准的非孕成人治疗剂量范围,孕前已开始购买者尤其高。
  • 作者认为需了解母体医用大麻暴露风险及高剂量使用驱动因素,以更好指导咨询和减少伤害。

研究设计与样本

  • 描述性探索性分析,链接阿肯色州医用大麻卡登记库、药房数据库和出生证明记录,并关联国家健康社会决定因素数据库。
  • 研究时段为2019年5月11日至2022年8月31日,共纳入72,992例妊娠。

主要发现

  • 1,185例(1.62%)孕期购买医用大麻,其中774例(65.3%)为持续使用者,411例(34.7%)为孕期起始使用者;另有94例在孕前90天内购买但孕前停止。
  • 与非购买者相比,购买者更可能≥30岁(aOR=1.34;P<.0001)和吸烟(aOR=1.64;P<.0001),更不可能为非西班牙裔黑人(aOR=0.44;P<.0001)、已婚(aOR=0.68;P<.0001)和有私人保险(aOR=0.69;P=.0001)。
  • 孕期日均购买THC为137.36(170.04)mg/d;持续使用者孕期日均THC购买量为起始使用者的1.54倍(95%CI 1.32-1.78),孕前日均THC购买量为 discontinued 者的3.84倍(95%CI 2.66-5.55)。
  • 持续使用者日均THC调整均值比(AMR)为起始使用者的1.82倍(P<.0001);<20岁(AMR=0.52;P=.0021)、有私人保险(AMR=0.81;P=.0093)、接受产前保健(AMR=0.72;P=.0420)、居住于小都市区(AMR=0.71;P=.0070)或小城镇(AMR=0.67;P=.0095)、居住于家庭食品券领取率较高社区(AMR=0.78;P=.0424)者日均THC较低。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Medical cannabis (MC) use has increased among pregnant women, yet little is known about the quantity, product types, and timing of use. This study conducted a population-level analysis of MC purchasing patterns among pregnant women in Arkansas. STUDY DESIGN: This descriptive exploratory analysis examined MC purchasing among pregnant women in Arkansas from May 11, 2019 to August 31, 2022, following MC availability. Data from three statewide data sources, the MC Card Registry (patient and qualifying condition data), MC Dispensary Database (transactions and product details), and Birth Certificate Records (maternal demographics and obstetric diagnoses), were linked with the national Social Determinants of Health Database, which provided neighborhood-level socioeconomic indicators. Descriptive statistics summarized maternal and purchasing characteristics and identified factors associated with the amount of purchased delta-9-tetrahydrocannabinol (THC), cannabis main psychoactive ingredient. RESULTS: Of the 72,992 pregnancies, 1185 (1.62%) included MC purchases during pregnancy. Among these, 774 (65.3%) were continuers, defined as those with MC purchases within 90 days prior to pregnancy that continued during pregnancy, and 411 (34.7%) initiated MC beginning during pregnancy. An additional 94 pregnancies purchased MC in the 90 days prior to pregnancy but discontinued by pregnancy onset. Compared to nonpurchasers, MC purchasers were more likely to be ≥30 years old (adjusted odds ratio (aOR)=1.34; P<.0001) and tobacco smokers (aOR=1.64; P<.0001) and less likely to be non-Hispanic Black (aOR=0.44; P<.0001), married (aOR=0.68; P<.0001), and privately insured (aOR=0.69; P=.0001). The mean (SD) daily THC purchased was 137.36 (170.04) mg/d. Continuers purchased 1.54 (95% CI, 1.32-1.78) times more daily THC during pregnancy than initiators and 3.84 (95% CI, 2.66-5.55) times more prepregnancy THC than discontinuers. The adjusted mean ratio (AMR) of daily THC was 1.82 (P<.0001) times higher among continuers compared to initiators, and lower for women <20 years (AMR=0.52; P=.0021), privately insured (AMR=0.81; P=.0093), receiving prenatal care (AMR=0.72; P=.0420), residing in micropolitan (AMR=0.71; P=.0070) or small-town areas (AMR=0.67; P=.0095), or residing in neighborhoods with higher household food-stamp receipt (AMR=0.78; P=.0424). CONCLUSIONS: The mean daily THC purchased during pregnancy exceeded therapeutic dosing ranges established for FDA-approved cannabinoid formulations in nonpregnant adults and was particularly high among women initiating MC purchase prepregnancy. These findings highlight the need to understand the risks of maternal MC exposure and the drivers to high-dose use, to better guide counseling and reduce harm, particularly from high-dose THC.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. ElHassan NO, Farnam C, Thompson JW, et al. From card to cradle: examining medical cannabis purchasing among pregnant women in Arkansas. Am J Obstet Gynecol MFM. 2025. PMID: 41317990. doi:10.1016/j.ajogmf.2025.101857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。